Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience

Bone Marrow Transplantation volume 45, pages 1502–1507 (2010)Cite this article

Subjects

Abstract

Haematopoietic SCT (HSCT) offers the only potentially curative option in chronic myelomonocytic leukaemia (CMML). In this study, we report on single-centre results of 18 patients with CMML who have undergone allogeneic HSCT. The median age of patients was 54 years. Seven patients had AML, which had transformed from CMML. Overall, 11 patients received stem cells from an unrelated donor. A total of 15 patients received a T-cell-depleted fludarabine/BU-based reduced-intensity conditioning HSCT. The actuarial 3-year OS, non-relapse mortality (NRM) and relapse incidence for the cohort was 31±11%, 31±14% and 47±13%, respectively. Patients with favourable cytogenetics had a 3-year disease-free survival of 65±17%, whereas none of the seven patients with intermediate or poor risk cytogenetics survived beyond 2 years (P<0.01). No patients with favourable risk cytogenetics died from NRM causes, while the 2-year NRM for the intermediate/poor risk cytogenetics subgroup was 71±22% (P<0.02). In terms of disease status at transplantation, patients who had <5% BM blasts had a 3-year disease-free survival of 46.9±19% compared with those with >5% blasts at the time of transplantation (that is, 20.0±13%). Recipient age, type of conditioning regimen or stem cell dose did not have a significant impact on overall outcomes. Our data support existing evidence that allogeneic HSCT is a feasible therapeutic option for CMML, with the ability to attain long-term remission among patient subgroups.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Jaffe EHN, Stein H, Vardiman JW . World Health Organisation classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe EHN, Stein H, Vardiman JW (eds). IARC Press: Lyon, France, 2001.

  2. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukaemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840–849.

    Article  CAS  PubMed  Google Scholar 

  3. Benesch M, Deeg J . Haemopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 2003; 78: 981–990.

    Article  PubMed  Google Scholar 

  4. Kröger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A et al. Allogeneic stem cell transplantation of adult CMML: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67–73.

    Article  PubMed  Google Scholar 

  5. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616–1623.

    Article  CAS  PubMed  Google Scholar 

  6. Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006; 135: 201–209.

    Article  Google Scholar 

  7. Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007; 138: 517–526.

    Article  CAS  PubMed  Google Scholar 

  8. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  9. Sullivan KM . Graft versus host disease. In: Thomas ED, Blume KG, Forman SJ, (eds). Hematopoietic Cell Transplantation. Blackwell Sciences: Malden, MA, 1999, 515–536.

    Google Scholar 

  10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  11. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukaemia. Bone Marrow Transplant 2006; 37: 1003–1008.

    Article  CAS  PubMed  Google Scholar 

  12. Ocheni S, Kröger N, Zabelina T, Zander AR, Bacher U . Outome of allo-SCT for chronic myelomonocytic leukaemia. Bone Marrow Transplant 2009; 43: 659–661.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK

    P Krishnamurthy, Z Y Lim, W Nagi, M Kenyon, A Mijovic, R Ireland, J Marsh, A Y L Ho, G J Mufti & A Pagliuca

  2. Division of Cancer Studies, Kings College London, London, UK

    Z Y Lim, G J Mufti & A Pagliuca

Authors
  1. P Krishnamurthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z Y Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Nagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Kenyon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Mijovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Ireland
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Y L Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Pagliuca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Pagliuca.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishnamurthy, P., Lim, Z., Nagi, W. et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 45, 1502–1507 (2010). https://doi.org/10.1038/bmt.2009.375

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.375

Keywords

This article is cited by

Search

Advanced search

Quick links